ClinicalTrials.gg
Status unknownNCT05085587Updated Oct 20, 2021

Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

A Phase 1 interventional study of Test and Reference in Bioequivalence and Asthma, sponsored by Respirent Pharmaceuticals Co Ltd.. Status unknown at 1 site in Greece. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-20.

Sponsored by Respirent Pharmaceuticals Co Ltd. · Phase 1, Interventional, and Other

The sponsor has not verified this record recently (last verified Oct 2021), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Planned enrollment
126th of 146
18 · median 100
Started
2021
with 4 others
Phase 1
22 of 147
none open now
Registered
142nd of 147
by date
Lead sponsor
7 of 147
Respirent Pharmaceuticals Co Ltd.

Among the 147 studies testing fluticasone in Asthma, this one is the 126th largest by planned enrollment of the 146 interventional ones that give a count, is one of 5 that started in 2021, is one of 22 in phase 1, and was the 142nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder

Read the detailed description

A bioequivalence study of a single dose of the fixed-dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder administered from Fluticasone propionate 250 mcg and Salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals (test-Τ) as 2 inhalations and ADVAIR DISKUS® 250/50 mcg inhalation powder/GSK (reference-R) in healthy volunteers under fasting conditions. The study will be one-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory blinded

03

Conditions studied

  • Bioequivalence
  • Asthma

Browse trials for

Keywords

  • bioequivalence
  • fluticasone propionate
  • salmeterol xinafoate
  • ADVAIR
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy volunteers of both genders, aged ≥18 and ≤55 years.
  2. Subjects with (ΒΜΙ) ≥18.5 and \<30.0 kg/m2.
  3. Healthy volunteers are declared healthy based on medical history, physical examination, , pulmonary function test (a (FEV1) >=90% of the predicted normal value), and clinical laboratory values within the laboratory stated normal range; if not within this range, they must be without any clinical significance according to the Investigator.
  4. Females who participate in the study are either at reproductive age i.e.pre-menopausal or unable to gestate [i.e. (absence of menses for 12 months prior to drug administration), hysterectomy, bilateral oophorectomy, tubal ligation at least 6 months prior to drug administration].
  5. Subjects that are non-smokers.
  6. Subjects that, in the opinion of the principal investigator/medical officer, are able to communicate and comply with the study procedures and protocol restrictions as evidenced by the Form (ICF) duly read, signed and dated by the subject prior to study initiation.
  7. Subjects able to use the inhalers according to given instructions, as judged by the Investigator or study nurse.

Exclusion criteria

Exclusion Criteria:

  1. to the active substance(s) or to the (lactose which contains small amounts of milk protein may cause allergic reactions) or related class (any sympathomimetic drug or any inhaled, intranasal, or systemic therapy) of the medicinal product
  2. illness or surgery within 12 weeks prior to dosing.
  3. Clinically significant abnormalities or vital sign abnormalities (seated systolic blood pressure \<90 or >140 mmHg, seated diastolic blood pressure \<50 or >90 mmHg or heart rate less than 50 or over 100 bpm) at screening.
  4. Clinically significant history or presence of chronic bronchitis, emphysema,asthma or any other lung disease.
  5. History or presence of pulmonary tuberculosis.
  6. Viral or bacterial, upper or lower respiratory tract infection or sinus or middle ear infection within 12 weeks prior to the screening visit.
  7. History or presence of significant cardiovascular, endocrinal, neurologic, immunological, psychiatric or metabolic disease.
  8. History of significant alcohol or drug abuse within one year prior to the screening visit.
  9. Regular use of alcohol within six months prior to screening visit (more than 14 alcohol units per week) [1Unit =150 ml of wine, 360 ml of beer, or 45 ml of 40% alcohol].
  10. Inability to abstain from alcohol for the duration of study period.
  11. Presence of disease markers for , or at screening.
  12. Positive results for drugs of abuse (barbiturates, marijuana, opioids, benzodiazepines and methadone) in saliva before each administration.
  13. Positive alcohol breath test before each administration.
  14. Use of soft drugs (such as marijuana) within three months prior to screening or hard drugs such as crack, cocaine or heroin within one year prior to screening visit
  15. Intake of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers are barbiturates, carbamazepine, phenytoin, glucocorticoids, rifampin/rifabutin; examples of inhibitors are, erythromycin, ketoconazole, indinavir, cobicistat-containing products) within one month prior to administration of the study medication. Under these circumstances, subject inclusion will be judged by the principal investigator.
  16. History of peptic ulcer, other gastrointestinal disorders (e.g. chronic diarrhoea, irritable bowel syndrome) or unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting) or significant hepatic, renal or other condition that is known to interfere with the absorption, distribution, metabolism or excretion of the drug.
  17. Use of oral or parenteral corticosteroids in the previous twelve (12) weeks
  18. Eye disorders especially Glaucoma (or a family history of glaucoma)
  19. Use of prescription medication (within 14 days prior to the first administration of study medication) or over-the-counter (OTC) products (including food supplements vitamins and herbal supplements) within one week (7 days) prior to the first administration of study medication, except for topical products without systematic absorption. are allowed.
  20. Vaccination for prophylaxis from seasonal flu or any other vaccination within seven days prior to administration
  21. History of allergy to any food, intolerance or special diet, that in the opinion of the medical sub-investigator could contraindicate the subject's participation in the study.
  22. A depot injection or an implant of any drug (except hormonal contraceptives) within 3 months prior to treatment administration.
  23. Donation of plasma (500 ml) within 7 days prior to treatment administration.
  24. Donation of whole blood or loss of whole blood ≥ 500 ml prior to administration of the study medication within 30 days prior to treatment administration.
  25. Participation in another clinical trial simultaneously.
  26. Subjects receiving special diet or having intolerance in any of the provided study meals or refusing to eat the study meals
  27. Application of tattoo or body piercing within 30 days prior to treatment administration.
  28. Non-tolerance to venipuncture.
  29. Breastfeeding women.
  30. Positive pregnancy test at screening
  31. Females of reproductive age that had sexual intercourse with a non-sterile male partner without protection within 14 days prior to drug administration

Reliable contraception methods are considered the following:

  • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal or transdermal
  • progestogen-only hormonal contraception associated with inhibition of ovulation oral, implanable or injectable
  • intrauterine device (IUD)
  • intrauterine hormone-releasing system (IUS)
  • bilateral tubal occlusion
  • vasectomised partner
  • sexual abstinence
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Test Product

    Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals

    Drug: Test

  • Active comparator
    Reference Product

    ADVAIR DISKUS 250/50

    Drug: Reference

Interventions

  • DrugTest

    2 inhalations of Test and Reference product in each study period

    Also known as: Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals

  • DrugReference

    2 inhalations of Test and Reference product in each study period

    Also known as: ADVAIR DISKUS 250/50

06

What researchers measure

Primary outcomes

  1. Cmax for Fluticasone Propionate (FP)

    Maximum plasma concentration, it is read directly from the raw data

    Time frame: 3, 5, 10, 15, 30, 45 minutes, 1.00 hour, 1 hour and 20 minutes, 1 hour and 40 minutes, 2.00 hours, 2 hours and 30 minutes, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00, 16.00, 24.00 and 36:00 hours post-administration]

  2. Cmax for Salmeterol

    Maximum plasma concentration, it is read directly from the raw data

    Time frame: Time Frame: 3, 5, 10, 15, 30, 45 minutes, 1.00 hour, 1 hour and 20 minutes, 1 hour and 40 minutes, 2.00 hours, 2 hours and 30 minutes, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00, 16.00, 24.00 and 36:00 hours post-administration]

  3. AUC(0-t) for Fluticasone Propionste (FP)

    Area under the plasma concentration curve from time 0 to the last measured concentration at time t

    Time frame: Time Frame: 3, 5, 10, 15, 30, 45 minutes, 1.00 hour, 1 hour and 20 minutes, 1 hour and 40 minutes, 2.00 hours, 2 hours and 30 minutes, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00, 16.00, 24.00 and 36:00 hours post-administration]

  4. AUC(0-t) for Salmeterol

    Area under the plasma concentration curve from time 0 to the last measured concentration at time t

    Time frame: Time Frame: 3, 5, 10, 15, 30, 45 minutes, 1.00 hour, 1 hour and 20 minutes, 1 hour and 40 minutes, 2.00 hours, 2 hours and 30 minutes, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00, 16.00, 24.00 and 36:00 hours post-administration]

Secondary outcomes

  1. AUC0-∞

    Area under the plasma concentration-time curve extrapolated to infinity AUC0-∞=AUC0-t+Ct/λz. Ct is the last measured concentration and λz is the apparent terminal elimination rate constant

    Time frame: up to 36 hours post-administration

  2. Tmax

    Time until Cmax is reached, it is read directly from the observed concentrations

    Time frame: up to 36 hours post-administration

  3. t1/2

    Plasma concentration halflife, it is calculated from the ratio 0.693/λZ

    Time frame: up to 36 hours post-administration

  4. λz

    Terminal elimination rate constant, calculated from the slope of the final phase of the ln-concentration curve versus time with regression analysis

    Time frame: up to 36 hours post-administration

  5. Residual Area

    \[AUC(0-∞)-AUC(0-t)\]/AUC(0-∞)\]

    Time frame: up to 36 hours post-administration

07

Study locations

1 site
  • BECRO Clinical Facility
    Larissa, Thessaly 41100, Greece
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Oct 2021, 0 months after the start.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's planned 0 months is below that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2021
First posted
Oct 20, 2021
StartActual
Oct 1, 2021
Primary completionEst.
Oct 25, 2021
CompletionEst.
Dec 30, 2021
Last update
Oct 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05085587
Collaborators
Becro Ltd.
Responsible party
Sponsor
First posted
Oct 20, 2021
Start date
Oct 1, 2021
Primary completion
Oct 25, 2021 (estimated)
Completion
Dec 30, 2021 (estimated)
Last update
Oct 20, 2021

Study contacts

Chrysoula Doxani, MD, MSc, PhD
principal investigator · Becro Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion